Gastroenterology
Digestive system clinical trials
Conditions of the stomach, intestines, liver, and the rest of the digestive tract. We’re tracking 7,606 recruiting studies in this area right now.
By phase
- Not applicable4,685
- Phase 21,189
- Phase 1568
- Phase 3457
- Phase 1/Phase 2368
- Phase 4229
- Phase 2/Phase 3110
Top conditions
- Colorectal Cancer479
- Pancreatic Cancer287
- Gastric Cancer283
- Hepatocellular Carcinoma256
- Esophageal Cancer189
- Rectal Cancer168
- Breast Cancer146
- Crohn Disease134
- Ulcerative Colitis129
- Colon Cancer114
- Hepatocellular Carcinoma (HCC)112
- Liver Cancer99
- Lung Cancer95
- Inflammatory Bowel Diseases94
- Pancreas Cancer90
- Ovarian Cancer89
- Esophageal Squamous Cell Carcinoma86
- Cystic Fibrosis77
Leading sponsors
- Fudan University100
- Sun Yat-sen University85
- Mayo Clinic75
- Second Affiliated Hospital, Zhejiang University, School of Medicine56
- Chinese University of Hong Kong55
- M.D. Anderson Cancer Center55
- Assistance Publique - Hôpitaux de Paris53
- Sixth Affiliated Hospital, Sun Yat-sen University51
- National Cancer Institute (NCI)50
- National Taiwan University Hospital45
Where studies are running
- California442
- Arizona190
- Texas140
- Alabama129
- Florida127
- New York120
- Massachusetts119
- Maryland88
- Ohio80
- Illinois69
Recruiting studies7,606 total
- NCT07620574Enrolling by invitationPhase 3
Long-Term Study Continuing Cancer Treatment from Previous Trial
This study lets people who were in an earlier Exelixis cancer treatment trial continue receiving the same treatment if it's still helping them. It's designed to see how safe and effective the treatment is over a longer period.
Bay Shore, New YorkAges Any age - NCT07612267RecruitingPhase 4
Mirikizumab Levels in Breast Milk During Treatment
This study measures how much of the medication mirikizumab passes into breast milk when mothers take it for their approved medical condition. The goal is to understand if it's safe for breastfeeding infants when mothers are receiving this treatment.
Glenview, IllinoisAges 3 weeks+ - NCT07618377RecruitingPhase 1
New Drug for Gastrointestinal Tumors After Multiple Treatments
This study tests a new drug called DCC-2618 for patients with GIST (a rare stomach/intestinal cancer) who have already tried at least three other treatments. The goal is to see if this drug can slow or shrink tumors in patients whose cancer has stopped responding to standard medications.
Kashiwa, ChibaAges 18 years+ - NCT06704321Recruiting
Effects of TOTUM-448 on liver fat and heart health
This trial tests a supplement called TOTUM-448 to see if it can reduce liver fat and improve heart health in people with a fatty liver condition (MASLD). If you have excess liver fat and are overweight, this study could help find new ways to manage your condition.
Québec, QuebecAges 18–75 - NCT06706700Recruiting
Biomarkers to predict cancer risk in pancreatic IPMN
This trial studies whether blood markers can help predict which pancreatic IPMNs are likely to become cancerous. If successful, it could help doctors decide when surgery is needed.
Milan, ItalyAges 18 years+ - NCT05000697Recruiting
Watch-and-wait or chemo after rectal cancer radiation
This trial studies people with early-to-mid stage distal rectal cancer who may get radiation and chemotherapy, with an option that may include an extra drug (oxaliplatin). It also tests whether some people can safely follow a “watch and wait” plan instead of immediate additional treatment, aiming to reduce overtreatment while keeping cancer control.
Buenos AiresAges 18 years+ - NCT04191395Recruiting
Study of treatments for long-term inflammatory diseases
This study looks at how chronic inflammatory illnesses progress over time and how treatments affect symptoms and disease markers. You may be invited if you’re receiving care for certain bowel, joint, or skin inflammatory conditions at the hospital.
BesançonAges 18 years+ - NCT05529940RecruitingPhase 3
FOLFIRINOX around surgery for resectable pancreatic cancer
This trial compares giving chemotherapy with FOLFIRINOX before and after surgery versus giving it mainly after surgery for people with resectable pancreatic duct cancer. It aims to improve outcomes by timing the treatment around the operation.
SeoulAges 19–80 - NCT05484908Recruiting
Tested treatment for hepatitis B-related liver cancer after immunotherapy
This trial studies whether the ALSS treatment is safe and effective for people with hepatitis B-related hepatocellular carcinoma who recently received immune checkpoint inhibitors. It may help improve outcomes for certain liver-related complications after immunotherapy, based on how their liver tests look.
Guangzhou, GuangdongAges 18–65 - NCT06697691Recruiting
Predicting rebleeding risk after upper gut bleeding
This study aims to create a tool that helps doctors predict if a patient with upper gut bleeding (not from veins) will rebleed while still in the hospital. It uses information from your hospital stay to better understand your risk and improve care.
Wuhan, HubeiAges 18 years+ - NCT06637215Recruiting
Day surgery for colorectal cancer
This study tests whether a same-day surgery approach for colorectal cancer is safe and effective. It uses small incisions and special pain management to help you recover faster at home with a caregiver nearby.
Shenyang, LiaoningAges 18–75 - NCT06708858RecruitingPhase 2
Studying surufatinib with chemo and immunotherapy for advanced bile duct cancer
This trial tests a combination of a targeted therapy (surufatinib), chemotherapy (gemcitabine and cisplatin), and an immunotherapy (durvalumab or pembrolizumab) for people with advanced bile duct cancer that hasn't been treated with systemic therapy before. The goal is to see if this combination can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT04310787Recruiting
Tracking outcomes in adults with hepatitis B liver failure
This study looks at long-term survival in people ages 18–65 who are hospitalized with hepatitis B–related acute-on-chronic liver failure. It may help doctors better predict prognosis and improve care for people with this serious condition.
Guangzhou, GuangdongAges 18–65 - NCT02883647Recruiting
Stopping antiviral treatment in chronic hepatitis B
This trial studies what happens after stopping long-term hepatitis B antiviral medicine in people whose virus has stayed controlled. It also follows patients over time to see how well they remain stable and safe after stopping.
Guangzhou, GuangdongAges 18–65 - NCT06707129Recruiting
New criteria to see if NASH liver scarring has reversed
This study is creating better ways to measure if liver scarring from NASH (a type of fatty liver disease) has improved. It may help doctors know if treatments are working.
Beijing, Beijing MunicipalityAges 18–70 - NCT03920618Recruiting
Testing three HBV medicines for severe liver flare (ACLF)
This study compares three hepatitis B (HBV) medicines to see which treatment helps people with a severe liver flare. You may be eligible if you have confirmed HBV and lab results showing significant liver stress.
Guangzhou, GuangdongAges 12–65 - NCT04597164Recruiting
Test a hepatitis B–targeted treatment for serious liver failure
This trial studies a combination approach called DPMAS and low-volume plasma exchange for people with hepatitis B–related acute-on-chronic liver failure. If you qualify, the goal is to improve your liver function and reduce serious complications from liver failure.
Guangzhou, GuangdongAges 18–65 - NCT05475613RecruitingPhase 2
Immunotherapy to shrink advanced liver cancer before transplant
This trial tests an immunotherapy “downstaging” plan to shrink hepatocellular carcinoma (a type of liver cancer) so it may become treatable with a liver transplant. You may be eligible if your cancer is beyond transplant limits but is still only in the liver, and you meet specific liver function and health requirements.
Guangzhou, GuangdongAges 18–75 - NCT06075199Recruiting
Study of stomach lining changes for cancer risk
This study follows people with intestinal metaplasia (a change in the stomach lining) over time to better understand who might develop stomach cancer. It does not test a new treatment but aims to improve prediction and prevention.
SeoulAges 18 years+ - NCT06405139RecruitingPhase 2
Chemo combo (nanoliposomal irinotecan, oxaliplatin, capecitabine) before surgery for locally advanced colorectal cancer
This trial tests a combination of three chemotherapy drugs (nanoliposomal irinotecan, oxaliplatin, and capecitabine) given before surgery to shrink locally advanced colorectal cancer that cannot be treated with radiation. The goal is to make the tumor removable with a better chance of complete removal (R0 resection).
BeijingAges 18–70 - NCT06709417RecruitingPhase 2
Immunotherapy plus chemo and radiation for advanced esophageal cancer
This trial is testing whether giving a combination of an immunotherapy drug (sintilimab) with chemotherapy, followed by radiation plus more chemotherapy (concurrent chemoradiotherapy), can help people with advanced esophageal cancer that cannot be removed surgically. The goal is to see if this approach shrinks the tumor and improves outcomes.
Shanghai, Shanghai MunicipalityAges 20–75 - NCT06709690Recruiting
AI-powered PET/MR scanner for children with suspected cancer
This study tests a new, fast, and quiet AI-powered PET/MR scanner to take detailed pictures of children with suspected cancer. It aims to make the imaging experience easier and more comfortable for kids.
Shanghai, Shanghai MunicipalityAges Up to 18 years - NCT06709885RecruitingPhase 2
HDAC inhibitor with chemoimmunotherapy before colon cancer surgery
This trial tests adding an HDAC inhibitor to standard chemotherapy and immunotherapy before surgery for a type of colon cancer called pMMR that has grown into nearby fat or deeper. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06710665Recruiting
Predicting adjuvant therapy success after esophageal cancer surgery
This trial looks at how well the tumor responded to chemotherapy or radiation before surgery, to see if that can help doctors decide next steps like additional treatment. It may help people with esophageal squamous cell cancer who had the tumor removed completely after initial therapy.
Fuzhou, FujianAges 18 years+
Common questions
- How many digestive system clinical trials are recruiting?
- Clin2 is tracking 7,606 recruiting gastroenterology studies from the U.S. registry right now, out of 11,952 we cover in this area in total.
- What does “Digestive system” cover here?
- Conditions of the stomach, intestines, liver, and the rest of the digestive tract. We group each study into digestive system based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a digestive system trial near me?
- Use the search to filter digestive system studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.